Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [1938]
News [3134]
Articles [127]
Editorials [3]
Conferences [120]
elearning [13]
New targeted treatments for blood cancers: Multiple myeloma, non-Hodgkin...
Dr Merry-Jennifer Markham - University of Florida, Florida, USA
New targeted treatments for blood cancers: Multiple myeloma, non-Hodgkin lymphoma, genomic marker mismatch repair and myelofibrosis ( Dr Merry-Jennifer Markham - University of Florida, Florida, USA )
30 May 2015
Targeted drug daratumumab shows promise in heavily treatment-resistant multiple...
Dr Saad Zafar Usmani - Levine Cancer Institute, Charlotte, USA
Targeted drug daratumumab shows promise in heavily treatment-resistant multiple myeloma ( Dr Saad Zafar Usmani - Levine Cancer Institute, Charlotte, USA )
30 May 2015
Ibrutinib combination regimen shows substantial benefits in relapsed CLL
Dr Asher Chanan-Khan - Mayo Clinic, Jacksonville, USA
Ibrutinib combination regimen shows substantial benefits in relapsed CLL ( Dr Asher Chanan-Khan - Mayo Clinic, Jacksonville, USA )
30 May 2015
Novel JAK inhibitor pacritinib proves effective for easing symptoms of...
Dr Ruben Mesa - Mayo Clinic Cancer Center, Scottsdale, USA
Novel JAK inhibitor pacritinib proves effective for easing symptoms of myelofibrosis ( Dr Ruben Mesa - Mayo Clinic Cancer Center, Scottsdale, USA )
30 May 2015
New ibrutinib combination regimen shows substantial benefits in relapsed...
Prof Asher Chanan-Khan - Mayo Clinic, Jacksonville, USA
New ibrutinib combination regimen shows substantial benefits in relapsed chronic lymphocytic leukaemia ( Prof Asher Chanan-Khan - Mayo Clinic, Jacksonville, USA )
30 May 2015
Obinutuzumab doubles remission duration in patients with relapsed, indolent non...
Dr Laurie Helen Sehn - BC Cancer Agency, Vancouver, Canada
Obinutuzumab doubles remission duration in patients with relapsed, indolent non-hodgkin lymphoma ( Dr Laurie Helen Sehn - BC Cancer Agency, Vancouver, Canada )
30 May 2015
First-in-class targeted drug daratumumab shows promise in heavily treatment...
Dr Saad Zafar Usmani - Levine Cancer Institute, Charlotte, USA
First-in-class targeted drug daratumumab shows promise in heavily treatment-resistant multiple myeloma ( Dr Saad Zafar Usmani - Levine Cancer Institute, Charlotte, USA )
30 May 2015
ecancermedicalscience editor's choice for May 2015
Prof Gordon McVie - ecancer and European Institute of Oncology, Milan, Italy
ecancermedicalscience editor's choice for May 2015 ( Prof Gordon McVie - ecancer and European Institute of Oncology, Milan, Italy )
26 May 2015
Virtual learning environment as a tool to provide laboratory training for...
Dr Nita Prasannan - Guy's Hospital, London, UK
Virtual learning environment as a tool to provide laboratory training for hematology registrars ( Dr Nita Prasannan - Guy's Hospital, London, UK )
6 May 2015
Analysis of iron status in paediatric acute lymphoblastic leukaemia
Dr Charlotte Brierley - Royal Hospital for Sick Children, Edinburgh, UK
Analysis of iron status in paediatric acute lymphoblastic leukaemia ( Dr Charlotte Brierley - Royal Hospital for Sick Children, Edinburgh, UK )
6 May 2015
New approaches to diffuse large B-cell lymphoma
Dr Andrew Davies - University Hospital Southampton NHS Foundation Trust...
New approaches to diffuse large B-cell lymphoma ( Dr Andrew Davies - University Hospital Southampton NHS Foundation Trust, Southampton, UK )
6 May 2015
Latest in novel approaches to CLL and MCL
Professor Peter Hillmen - Leeds Teaching Hospitals NHS Trust, Leeds, UK
Latest in novel approaches to CLL and MCL ( Professor Peter Hillmen - Leeds Teaching Hospitals NHS Trust, Leeds, UK )
6 May 2015

More from ecancer

Register with ecancer to receive our newsletter

Register here

Explore patient resources at ecancerpatient

Visit site

Find out more about ecancer and the work we do

About ecancer

Support ecancer's work by making a donation